Lawsuit filed for Investors who lost money with shares of Replimune Group, Inc. (NASDAQ: REPL)

An investor, who purchased shares of Replimune Group, Inc. (NASDAQ: REPL), filed a lawsuit over alleged violations of Federal Securities Laws by Replimune Group, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and for certain investors are short and strict deadlines running. Deadline: September 22, 2025. NASDAQ: REPL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Woburn, MA based Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.

On July 22, 2025, Replimune Group, Inc. (NASDAQ: REPL) announced that it received a Complete Response Letter from the FDA rejecting its Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated that "the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness."

Shares of Replimune Group, Inc. (NASDAQ: REPL) declined from $17.00 per share on November 22, 2024, to as low as $2.68 per share on July 22, 2025.

The plaintiff claims that between November 22, 2024 and July 21, 2025, the misleading statements and/or failed to disclose that the Defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled, and that as a result, defendants' statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times

Those who purchased shares of Replimune Group, Inc. (NASDAQ: REPL) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.